Triptorelin extended release - Xbrane

Drug Profile

Triptorelin extended release - Xbrane

Alternative Names: Microrelin; Spherotide

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Primm srl
  • Developer Pooyesh Darou; Xbrane
  • Class Antineoplastics; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Endometriosis; Prostate cancer; Uterine leiomyoma
  • Clinical Phase Unknown Breast cancer; Precocious puberty

Most Recent Events

  • 24 Jul 2017 Xbrane Biopharma's partner Pooyesh Darou receives marketing authorisation approval in Iran under the local name Microrelin®
  • 13 Apr 2017 Preclinical trials in Prostate cancer in Denmark (IV-injection)
  • 13 Apr 2017 Xbrane plans a pivotal phase III trial in Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top